Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Our site is under planned maintenance. At this time, you will not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

The Future of Vaccinology

The Future of Vaccinology

Wednesday, March 30, 2022, 9:00 AM - Thursday, March 31, 2022, 5:30 PM EDT

New York City

Presented By

Microbiology and Infectious Diseases Discussion Group

The New York Academy of Sciences

 

Historically, vaccine development has been a slow process, though new scientific discoveries and technologies in the last quarter century accelerated advances in virology and vaccinology. More recently, a possible paradigm shift has emerged — the race to develop COVID-19 vaccines demonstrated massive achievements in speed and efficacy of new vaccine development using both old and novel vaccine platforms.

To better understand what we can learn from recent successes in vaccine development and deployment, this two-day conference will convene leaders in vaccinology, virology, immunology, biotechnology, microbiology, systems biology, and health policy. Session topics include a look back at advances in vaccine development, updates from present-day vaccinology, a discussion on how vaccine development can be strengthened based on COVID-19 vaccine learnings, pharma company pipeline updates, next generation vaccine adjuvants, improving immune measures, and more.

Scientific Organizing Committee

Annaliesa Anderson, PhD
Annaliesa Anderson, PhD

Pfizer

Greg Glenn, MD
Greg Glenn, MD

Novavax

Emmanuel Hanon
Emmanuel Hanon

Viomme

Wayne Koff, PhD
Wayne Koff, PhD

Human Vaccines Project

Melanie Brickman Borchard, PhD, MSc
Melanie Brickman Borchard, PhD, MSc

New York Academy of Sciences

Keynote Speakers

Emilio Emini, PhD
Emilio Emini, PhD

Bill and Melinda Gates Research Institute

Stanley Plotkin, MD
Stanley Plotkin, MD

University of Pennsylvania

Speakers

Kathrin Jansen, PhD
Kathrin Jansen, PhD

Pfizer

Hanneke Schuitemaker, PhD
Hanneke Schuitemaker, PhD

Janssen Vaccines & Prevention B.V.

Rino Rappuoli, PhD
Rino Rappuoli, PhD

GlaxoSmithKline

Sara Gilbert, PhD
Sara Gilbert, PhD

University of Oxford

Emilio Emini, PhD
Emilio Emini, PhD

Bill and Melinda Gates Research Institute

Stanley Plotkin, MD
Stanley Plotkin, MD

University of Pennsylvania

Kate Broderick, PhD
Kate Broderick, PhD

Inovio

Greg Glenn, MD
Greg Glenn, MD

Novavax

John Tsang, PhD
John Tsang, PhD

National Institute for Allergy and Infectious Diseases, NIH

W. Ripley Ballou, MD
W. Ripley Ballou, MD

IAVI

Robbert Van Der Most, PhD
Robbert Van Der Most, PhD

CEPI

Bali Pulendran, PhD
Bali Pulendran, PhD

Stanford University

Thomas Lingelbach
Thomas Lingelbach

Valneva

David Dowling, PhD
David Dowling, PhD

Harvard University

Nathalie Garçon, CSO, PharmD, PhD
Nathalie Garçon, CSO, PharmD, PhD

BIOASTER

Emmanuel Hanon, PhD
Emmanuel Hanon, PhD

Viome

Sabra Klein, PhD
Sabra Klein, PhD

Johns Hopkins University

Mark Davis, PhD
Mark Davis, PhD

Stanford University

Jamila Louahed, PhD
Jamila Louahed, PhD

GlaxoSmithKline

Jim Tartaglia, PhD
Jim Tartaglia, PhD

Sanofi Pasteur

Wednesday

March 30, 2022

8:30 AM

Check in and Breakfast

9:00 AM

WELCOME REMARKS

Speaker

Melanie Brickman Borchard, PhD, MSc
New York Academy of Sciences
9:20 AM

KEYNOTE SPEAKER

Speaker

Emilio Emini, PhD
Bill and Melinda Gates Research Institute

WHERE WE WERE

SESSION I: A Look Back at Advances in Vaccine Development

10:00 AM

KEYNOTE ADDRESS: Perseverance and Progress: Vaccinology in the Last 50 years

Speaker

Stanley Plotkin, MD
University of Pennsylvania
10:30 AM

Lessons from COVID-19: Comparative Advantages and Weaknesses of mRNA, Adenoviral Vector, and Protein–Adjuvant Vaccine Platforms

Speaker

Speaker to Be Announced
11:00 AM

Break

WHERE WE ARE

SESSION II: Present-Day Vaccinology

11:30 AM

Panel Discussion: How Can Vaccine Development Be Strengthened Based on COVID-19 Vaccine Learnings

Speakers

Moderator: To be Announced
Sara Gilbert, PhD
University of Oxford
Greg Glenn, MD
Novavax
Kathrin Jansen, PhD
Pfizer
Hanneke Schuitemaker, PhD
Janssen Vaccines & Prevention B.V.
12:10 PM

Lingering Hurdles — The Big 3: HIV, TB, and Malaria

Speaker

W. Ripley Ballou, MD
IAVI
12:40 PM

Lunch and Poster Session

SESSION II: Present-Day Vaccinology (Continued)

1:55 PM

Protecting the Vulnerable: Newborns, the Elderly, the Immunocompromised, and Individuals in Low-Resource Settings

Speaker

Robbert Van Der Most, PhD
CEPI
2:25 PM

Vaccine Durability

Speaker

Bali Pulendran, PhD
Stanford University

SESSION III: Short Talks Selected from Submitted Abstracts

2:55 PM

Speaker to Be Selected

3:05 PM

Speaker to Be Selected

3:15 PM

Break

SESSION IV: Pipeline Updates

3:45 PM

Late Stage Pipleine of Vaccines for Infectious Diseases

Speaker

Kathrin Jansen, PhD
Pfizer
4:10 PM

The Late Stage Pipeline of Vaccines for Infectious Diseases

Speaker

Greg Glenn, MD
Novavax
4:35 PM

Sanofi’s Late Stage Pipeline of Vaccines for Infectious Diseases

Speaker

Jim Tartaglia, PhD
Sanofi Pasteur
5:00 PM

Late-Stage Vaccine Developments for Infectious Diseases

Speaker

Rino Rappuoli, PhD
GlaxoSmithKline
5:25 PM

Closing Remarks, Day 1

Speaker

Melanie Brickman Borchard, PhD, MSc
New York Academy of Sciences
5:30 PM

End of Day 1

Thursday

March 31, 2022

8:30 AM

Check in and Breakfast

9:00 AM

WELCOME REMARKS

Speaker

Melanie Brickman Borchard, PhD, MSc
New York Academy of Sciences

WHERE ARE WE GOING

SESSION V: Vaccines for Chronic Infectious Diseases

9:05 AM

The Pathway and Lessons Learned from the Shingles Vaccine

Speaker

Jamila Louahed, PhD
GlaxoSmithKline
9:35 AM

Chronic Viral Infectious Diseases

Speaker

Speaker to Be Announced
10:05 AM

Chronic Bacterial Infectious Diseases, Learnings from the VLA15 Multivalent Recombinant Protein Vaccine for Lyme Disease

Speaker

Thomas Lingelbach
Valneva
10:35 AM

Break

SESSION VI: Next Generation Vaccine Adjuvants

11:05 AM

Adjuvanted Vaccines Targeted to Vulnerable Populations

Speaker

David Dowling, PhD
Harvard University
11:35 AM

Next Generation Vaccine Adjuvants

Speaker

Nathalie Garçon, CSO, PharmD, PhD
BIOASTER
12:05 PM

Lunch and Poster Session

SESSION VII: Immune Response to Vaccination

1:25 PM

The Impact of the Microbiome on Immunity

Speaker

Emmanuel Hanon, PhD
Viome
1:55 PM

Biological Sex and Age Affect Immunity Following Vaccination

Speaker

Sabra Klein, PhD
Johns Hopkins University

SESSION VIII: Making Immune Measures More Efficient, Agile, and Meaningful

2:25 PM

Immune Monitoring: Vaccination Indicators of Immunological Health and Responsiveness

Speaker

Mark Davis, PhD
Stanford University
2:55 PM

Systems Biology in Vaccine Design and Development

Speaker

John Tsang, PhD
National Institute for Allergy and Infectious Diseases, NIH
3:25 PM

Break

SESSION VIII: Continued

3:55 PM

Advances in Artificial Intelligence Tools to Speed Vaccine Development

Speaker

Kate Broderick, PhD
Inovio

SESSION IX: Closing Keynote

4:25 PM

What the Future Holds for Vaccine Development

Speaker

Speaker to Be Announced
5:05 PM

Closing Remarks

Speaker

Melanie Brickman Borchard, PhD, MSc
New York Academy of Sciences
5:15 PM

End of Day